Comparison
5q14 3 Microdeletion Syndrome C4304529 vs 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Clinical comparison between 5q14 3 Microdeletion Syndrome and 3 Beta Hydroxysteroid Dehydrogenase Deficiency for differential diagnosis and treatment planning.
5q14 3 Microdeletion Syndrome C4304529
A rare genetic condition involving deletion of a small region on chromosome 5, affecting brain development and often causing seizures and developmental issues.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
A rare genetic disorder affecting adrenal hormone production. It can cause ambiguous genitalia, salt-wasting crises, and hormonal imbalances. Treatment requires hormone replacement therapy and careful monitoring.
6 comparison axes
Onset
5q14 3 Microdeletion Syndrome C4304529
Variable
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
0-null
Onset patterns differ
Severity
5q14 3 Microdeletion Syndrome C4304529
severe
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
severe
Different severity levels
Chronic
5q14 3 Microdeletion Syndrome C4304529
Chronic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Chronic
Differing course
Communicable
5q14 3 Microdeletion Syndrome C4304529
No
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
No
Different transmission
Body System
5q14 3 Microdeletion Syndrome C4304529
congenital
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
Same/different system
Category
5q14 3 Microdeletion Syndrome C4304529
genetic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
Different category
Bottom line
5q14-3-microdeletion-syndrome-C4304529 and 3-beta-hydroxysteroid-dehydrogenase-deficiency-C0342471 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 5q14 3 Microdeletion Syndrome C4304529 | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | Discriminating power |
|---|---|---|---|
| Developmental delay or seizures | Often reported with brain-development effects and seizures; severity varies. | Not the defining feature; neurologic effects are not established as primary. | Moderate |
| Genital or adrenal crisis features | Not described as a characteristic endocrine presentation. | May include ambiguous genitalia, salt-wasting crisis, or hormonal imbalance. | High |
| Age and pattern of recognition | Onset is variable and often recognized through developmental concerns. | May present early, including in infancy, but timing is not uniform. | Moderate |
When to favor each condition
Choose 5q14 3 Microdeletion Syndrome C4304529 when
Unexplained developmental disorder with seizures
A chromosomal deletion affecting brain development is more consistent than an adrenal enzyme defect.
Moderate
Microarray or chromosomal testing suggests 5q14.3 loss
A detected deletion supports this diagnosis only after laboratory and clinical confirmation.
High
No genital ambiguity or salt-wasting features
Absence of endocrine crisis makes the adrenal disorder less likely, but does not exclude it.
Low
Choose 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 when
Infant with suspected adrenal insufficiency
Salt-wasting or shock raises concern for disordered adrenal steroid production.
High
Ambiguous genitalia with abnormal steroid pattern
This combination points toward a disorder of sex development and steroid synthesis.
Moderate
Need for ongoing hormone replacement is identified
Replacement and monitoring fit the endocrine disorder, not the microdeletion syndrome.
Moderate
How key tests differ
| Test | 5q14 3 Microdeletion Syndrome C4304529 | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May detect a small 5q14.3 deletion. | Not expected to identify the enzyme deficiency. | A deletion supports the left condition only with expert confirmation. |
| Steroid hormone profile | No characteristic adrenal steroid abnormality is established. | May show disordered adrenal steroid production; exact cutoffs are not stated here. | Abnormal results suggest endocrine disease but require specialist interpretation. |
| Electrolytes during illness | No specific salt-wasting pattern is established. | May show salt loss during crisis, without a universal cutoff. | Electrolyte changes are urgent findings, not a standalone diagnosis. |
Prognosis comparison
5q14 3 Microdeletion Syndrome C4304529
- Outcome
- Often chronic neurodevelopmental disability; exact prognosis is not established.
- Factors
- Deletion extent, seizures, developmental support, and associated findings may influence outcome.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
- Outcome
- Chronic endocrine condition; outcome depends on recognition and ongoing management.
- Factors
- Salt-wasting severity, hormone imbalance, treatment adherence, and monitoring may matter.
Time frame: Lifelong for both, with variable individual course.
Early recognition and coordinated specialist care are important; no mortality estimate is established.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Seizures and developmental impairment may occur. Primary complications are endocrine rather than neurodevelopmental. Neurologic burden is better aligned with the microdeletion, though individual outcomes vary. |
| Adrenal crisis | Not an established feature. Salt-wasting crisis can be life-threatening. Suspected crisis needs urgent clinical care; this comparison gives no treatment doses. |
| Long-term monitoring needs | Developmental, seizure, and supportive-care follow-up may be needed. Hormone replacement and endocrine monitoring are central. Both are chronic, but the monitoring targets differ. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion affecting development; the other is an inherited adrenal hormone-production disorder.
- HighUrgent warning signs
Poor feeding, vomiting, dehydration, or collapse in the endocrine disorder needs urgent assessment.
- MediumDiagnosis limits
An abnormal test is not automatically a diagnosis and should be interpreted by a clinician.